Adamas Pharmaceuticals Inc (ADMS) Shares Sold by California State Teachers Retirement System

California State Teachers Retirement System lowered its position in shares of Adamas Pharmaceuticals Inc (NASDAQ:ADMS) by 9.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,409 shares of the specialty pharmaceutical company’s stock after selling 2,505 shares during the quarter. California State Teachers Retirement System owned 0.10% of Adamas Pharmaceuticals worth $496,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at $109,000. SG Americas Securities LLC acquired a new stake in Adamas Pharmaceuticals during the 3rd quarter valued at $110,000. Quantbot Technologies LP acquired a new stake in Adamas Pharmaceuticals during the 3rd quarter valued at $119,000. Virtu KCG Holdings LLC acquired a new stake in Adamas Pharmaceuticals during the 2nd quarter valued at $184,000. Finally, Sei Investments Co. lifted its holdings in Adamas Pharmaceuticals by 1,105.0% during the 3rd quarter. Sei Investments Co. now owns 8,760 shares of the specialty pharmaceutical company’s stock valued at $185,000 after purchasing an additional 8,033 shares during the last quarter. 66.90% of the stock is owned by hedge funds and other institutional investors.

Shares of Adamas Pharmaceuticals Inc (NASDAQ ADMS) opened at $26.39 on Wednesday. The company has a current ratio of 8.35, a quick ratio of 8.32 and a debt-to-equity ratio of 0.41. Adamas Pharmaceuticals Inc has a 12 month low of $13.50 and a 12 month high of $44.00.

Several research analysts have weighed in on the company. Evercore ISI assumed coverage on Adamas Pharmaceuticals in a research report on Monday, October 30th. They set an “outperform” rating on the stock. Cowen set a $55.00 price objective on Adamas Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, December 13th. Northland Securities initiated coverage on Adamas Pharmaceuticals in a research report on Wednesday, November 29th. They set an “outperform” rating on the stock. Noble Financial raised their price target on Adamas Pharmaceuticals from $33.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Finally, Mizuho restated a “buy” rating and issued a $48.00 price target on shares of Adamas Pharmaceuticals in a research report on Tuesday, January 23rd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $44.86.

ILLEGAL ACTIVITY NOTICE: “Adamas Pharmaceuticals Inc (ADMS) Shares Sold by California State Teachers Retirement System” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://stocknewstimes.com/2018/02/21/adamas-pharmaceuticals-inc-adms-stake-lessened-by-california-state-teachers-retirement-system.html.

Adamas Pharmaceuticals Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply